Výsledky vyhledávání - "Estibalitz Montejo Rodrigo"

Precision Medicine Based on the Achievement of Sustained Undetectable Minimal Residual Disease (MRD) By Next-Generation Flow (NGF) and Imaging Leads to Significant Reduction in Risk of Progression of Patients with Multiple Myeloma (MM)

Autor: Alberto Saiz López, Alberto Cabrera Zubizarreta, Tomas Carrascosa Vallejo, Raquel Pérez Garay, Maria Jose Ereño Ealo, Cristina Cortes Fernández, Ana de Juan Arroyo, Jose Enrique De La Puerta Rueda, Javier Goikolea Ugarte, Ibone Saralegui Prieto, Mara Celis Alvarez, Isabel Uriarte, Amaia Casado Diez, Paula Arana Berganza, Natalia Maruri Machado, Paloma Ibarrondo Chamorro, Inmaculada Barredo Santamaría, Eukene Gainza González, Cristina Martinez Bilbao, Elixabete Pastor Ausin, Luis Atutxa Aresti, Eloisa Urrechaga Igartua, Leire Burgos, José María Ontañón Garcés, Bruno Paiva, Matxalen Olivares Salaverri, Begoña Sancho Garaizábal, Iñigo Vicente Olabarria, Garazi Letamendi Madariaga, Ane Aranbarri Larrañaga, Ianire Etxeguren Urkixo, Inés González Vallejo, Antonio Rodríguez, Estibalitz Montejo Rodrigo, Itxaso Amarika Ibarrondo, Jesus Ojanguren Bergaz

Publikováno v: Blood. 134:3170-3170

Background: Assessing MRD has become a standard procedure in clinical trials to evaluate treatment efficacy. In accordance with its consistent prognostic value, the International Myeloma Working Group added MRD-negative criteria into response guideli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b73f8dc58f79f257a48ff1f86b893b0b
https://doi.org/10.1182/blood-2019-125062

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání